HLB Pharmaceutical Co., Ltd. (KOSDAQ:047920)

Market Cap	153.90B -45.2%
Revenue (ttm)	236.59B +72.6%
Net Income	3.72B +84.4%
EPS	113.42 +80.0%
Shares Out	14.04M
PE Ratio	96.63
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,003
Open	10,840
Previous Close	10,710
Day's Range	10,840 - 11,190
52-Week Range	9,740 - 22,250
Beta	0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About HLB Pharmaceutical

HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, par...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 047920

Financial Performance

In 2025, HLB Pharmaceutical's revenue was 205.58 billion, an increase of 49.97% compared to the previous year's 137.08 billion. Earnings were 4.57 billion, an increase of 126.35%.